Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basimglurant randomized-withdrawal study in pain associated with trigeminal neuralgia
2024-514497-41-00Phase 3Authorised
- Sponsor
- Noema Pharma
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in trigeminal neuralgia (TN) comparing Basimglurant continuation with Placebo withdrawal arm (2 arms). Planned start Mar 2022; status: authorised.
02
Drugs
basimglurant
03
Conditions
trigeminal neuralgia (TN)
Beyond the preview
Go deeper on 2024-514497-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514497-41-00.